NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025

NextCure, Inc.

2022-Q3 EPS reported -$2.07

Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.
Cash, cash equivalents and marketable securities at Sept 30, 2022: $169.2M, down from $219.6M at Dec 31, 2021.
Q3 2022 net loss $18.9M vs $17.9M in Q3 2021; R&D expense flat at $13.5M, G&A up to $5.7M.
Cash runway extended by 15 months; now expected to fund operations into mid‑2025.
Advancing NC410 Phase 1b/2 combo trial, NC525 Phase 1 expected Q1 2023, and NC762 expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NextCure, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $18.9 million for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Net income: Net loss was $18.9 million for the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Net loss was $18.9 million for the quarter ended September 30, 202 2, as compared with a net loss of $17.9 million for the quarter ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.